To Evaluate the Efficacy and Safety of 'NDTx-01' in Patients With ASD or SCD

Inclusion Criteria:

• Children and adolescents between the ages of 10 and 18

• Diagnosed with autism spectrum disorder (ASD) or social communication disorder (SCD)based on the clinical judgment of a psychiatrist according to DSM-5 diagnosticcriteria

• Participants who are able to install 'NDTx-01' on an Android smartphone and use italone or with the help of their guardian

• Participants who are able to comply with the recommended application time for theinvestigational medical device (6 weeks, 30 times, 5 times a week)

• Participants who have agreed not to use any other medical devices besides theinvestigational medical device during the clinical trial

• Participants who agree that there should be no change in the use of drugs which cansignificantly affect one's sociality during the clinical trial (If there is a drugbeing taken during screening, it can be taken continuously, but the total dailydose, ingredients, etc., should remain unchanged until the end of the study visit.)

• Participants who agree not to participate in other Applied Behavior Analysis (ABA)treatment/rehabilitation/education, social treatment/rehabilitation/educationprogram (If there is treatment/rehabilitation/education being received duringscreening, it can be received continuously, but the number of applications andtreatment methods should remain unchanged until the end of the study visit.)

• Participants who and whose parents (legal guardians) have volunteered to participatein this clinical trial and have given written consent to the subject description andconsent form

• Participants willing to comply with the clinical trial procedures

Exclusion Criteria:

• A risk of clinically significant behavioral problems, emotion regulation problems,psychotic symptoms, self-harm, or other harm at a level that affects the treatmentprocess

• Severe acute/chronic medical or mental illness

• Serious trauma or surgery performed within 4 weeks before the screening date

• Participants with other disabilities such as severe neurological diseases (e.g.brain lesions, mental disorders, etc.)

• Participants who are currently participating in another clinical trial or haveparticipated in another clinical trial within 30 days before the screening date

• Participants with a previous history of using NDTx-01, the investigational device

• Participants who have a change in the usage or dosage of drugs which cansignificantly affect one's sociality, or a change in participation intreatment/rehabilitation/education programs that can significantly affect one'ssociality within 8 weeks before the baseline date of the clinical trial

• In other cases where the investigator determines that participation in the clinicaltrial is inappropriate due to ethical reasons or the possibility of influencing theresults of the clinical trial